التفاصيل البيبلوغرافية
| العنوان: |
Ex vivo T‐cell depletion vs post‐transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft‐vs‐host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. |
| المؤلفون: |
Montoro, Juan, Roldán, Elisa, Piñana, José Luis, Barba, Pere, Chorão, Pedro, Quintero, Abdiel, Hernani, Rafael, Ortí, Guillermo, Lorenzo, José Ignacio, Balaguer‐Roselló, Aitana, Salamero, Olga, Fox, Laura, Solves, Pilar, Gómez, Inés, Guerreiro, Manuel, Hernández Boluda, Juan Carlos, Sanz, Guillermo, Solano, Carlos, Sanz, Miguel Ángel, Valcárcel, David |
| المصدر: |
European Journal of Haematology; Jan2021, Vol. 106 Issue 1, p114-125, 12p |
| مصطلحات موضوعية: |
HEMATOPOIETIC stem cell transplantation, RAPAMYCIN, CYCLOPHOSPHAMIDE, GRAFT versus host disease, MYCOPHENOLIC acid |
| مستخلص: |
Objective: To compare the efficacy and safety of CD34+ selected ex vivo T‐cell depletion (TCD) vs post‐transplant cyclophosphamide, sirolimus, and mycophenolate mofetil (PTCy‐Sir‐MMF) as graft‐vs‐host disease (GVHD) prophylaxis. Methods: We retrospectively included patients who underwent allogeneic hematopoietic stem cell transplantation (allo‐HSCT) with either TCD (n = 38) or PTCy‐Sir‐MMF (n = 91). Results: Cumulative incidence of neutrophil and platelet recovery was 92% vs 99% (P =.06) and 89% vs 97% (P =.3) in TCD and PTCy‐Sir‐MMF, respectively. Cumulative incidences of aGHVD grade II‐IV, III‐IV, and moderate to severe cGVHD were 11% vs 19% (P =.2), 3% vs 2% (P =.9), and 3% vs 36% (P <.001) in TCD and PTCy‐Sir‐MMF, respectively. The 2‐year non‐relapse mortality, relapse, disease‐free and overall survival were 25% vs 8% (P =.01), 20% vs 16% (P =.2), 55% vs 76% (P =.004), 57% vs 83% (P =.004) for TCD and PTCy‐Sir‐MMF, respectively. Cumulative incidence of cytomegalovirus and Epstein‐Barr infection requiring therapy was 76% vs 40% (P <.001) and 32% vs 0% (P <.001) in TCD and PTCy‐Sir‐MMF, respectively. PTCy‐Sir‐MMF platform showed faster T‐cell reconstitution. Conclusions: PTCy‐Sir‐MMF provides better survival outcomes but is associated with higher risk of cGVHD compared to TCD. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
